Literature DB >> 16322382

GH responsiveness varies during the menstrual cycle.

Helena K Gleeson1, Stephen M Shalet.   

Abstract

OBJECTIVE: The GH-IGF-1 axis is affected by oestrogen. Both endogenous and exogenous oestrogen facilitates the central drive of pulsatile GH secretion. However, the effect on IGF-1 levels is more subtle, and a reduction in GH sensitivity has been proposed. The IGF generation test has confirmed reduced GH sensitivity with high doses of exogenous oestrogen. It is not known, however, whether fluctuant levels of endogenous oestrogen modify GH sensitivity. To investigate this further, women were challenged with the IGF-1 generation test at different stages of the menstrual cycle.
METHODS: Nine women (age 38(6) years (mean (s.d.)) with regular menstrual cycles were recruited. An IGF-1 generation test, s.c. injection of 7 mg GH, was performed in the early-follicular (EF), periovulatory (PO) and midluteal (ML) phases. IGF-1, insulin-like growth factor binding protein (IGFBP)-3 and acid-labile subunit (ALS) levels were measured at baseline and 24 h after GH administration.
RESULTS: Oestradiol levels were lower in the EF than PO or ML phases (32.6(7.8) vs 69.6(16.2) vs 66.6(23.6) pg/ml respectively (repeated measures ANOVA, P < 0.001)). Baseline IGF-1 was lower, but increment IGF-1 (peak minus baseline) was higher in the EF than PO or ML phases (baseline: 291.8(56.6) vs 335.0(55.2) vs 346.6(78.2) ng/ml (P = 0.008); increment IGF-1: 234.6(59.2) vs 194.7(37.8) vs 185.2(37.3) ng/ml (P = 0.008)).
CONCLUSIONS: Increased endogenous oestrogen levels are associated with only a modestly elevated baseline IGF-1 from midcycle onward despite a previously reported twofold increase in GH secretion. In parallel with this apparent GH insensitivity, increased endogenous oestrogen levels are associated with reduction in GH sensitivity evidenced by reduction in increment IGF-1. This may have clinical implications for women with isolated GH deficiency with regular menstrual cycles on a fixed dose of GH. This possibility requires further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322382     DOI: 10.1530/eje.1.02037

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  9 in total

1.  Changes in serum collagen markers, IGF-I, and knee joint laxity across the menstrual cycle.

Authors:  Sandra J Shultz; Laurie Wideman; Melissa M Montgomery; Kathleen N Beasley; Bradley C Nindl
Journal:  J Orthop Res       Date:  2012-03-02       Impact factor: 3.494

2.  Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Elena Varlamov; Chris G Yedinak; Justin S Cetas; Shirley McCartney; Aclan Dogan; Maria Fleseriu
Journal:  Endocrine       Date:  2017-10-17       Impact factor: 3.633

3.  Influence of gender on serum growth hormone, insulin-like growth factor-I and its binding protein-3 during aging.

Authors:  Chiou-Meei Lin; Yeou-Lih Huang; Zu-Yau Lin
Journal:  Yonsei Med J       Date:  2009-06-24       Impact factor: 2.759

4.  Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant.

Authors:  J Roemmler; M Bidlingmaier; J Schopohl
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

5.  Age-related changes in body composition of bovine growth hormone transgenic mice.

Authors:  Amanda J Palmer; Min-Yu Chung; Edward O List; Jennifer Walker; Shigeru Okada; John J Kopchick; Darlene E Berryman
Journal:  Endocrinology       Date:  2008-10-23       Impact factor: 4.736

Review 6.  IGF-I measurements in the diagnosis of adult growth hormone deficiency.

Authors:  Anita Y M Kwan; Mark L Hartman
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

7.  Effects of a single dose of N-Acetyl-5-methoxytryptamine (Melatonin) and resistance exercise on the growth hormone/IGF-1 axis in young males and females.

Authors:  Erika Nassar; Chris Mulligan; Lem Taylor; Chad Kerksick; Melyn Galbreath; Mike Greenwood; Richard Kreider; Darryn S Willoughby
Journal:  J Int Soc Sports Nutr       Date:  2007-10-23       Impact factor: 5.150

Review 8.  Hormonal Contraception and Bone Health in Adolescents.

Authors:  Laura K Bachrach
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-21       Impact factor: 5.555

Review 9.  The Specificities of Elite Female Athletes: A Multidisciplinary Approach.

Authors:  Carole Castanier; Valérie Bougault; Caroline Teulier; Christelle Jaffré; Sandrine Schiano-Lomoriello; Nancy Vibarel-Rebot; Aude Villemain; Nathalie Rieth; Christine Le-Scanff; Corinne Buisson; Katia Collomp
Journal:  Life (Basel)       Date:  2021-06-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.